Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Amino Acids

Zanubrutinib

Rituximab

Polatuzumab vedotin

Antineoplastic Agents, Immunological

Immunologic Factors

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunoconjugates

Tyrosine

Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1

Zanubrutinib, Polatuzumab vedotin and Rituximab

Peng Liu, Ph.D

Yian Zhang, Ph.D

This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma.

This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma.

* Primary objective: use ORR to evaluate the effectiveness of ZPR in treating R/R DLBCL patients
* Secondary objective: Evaluate the safety of ZPR treatment for R/R DLBCL patients
* The subjects received 6 cycles of ZPR regimen, one cycle every 21 days. Then Zanubrutinib alone will continue to be used until Zanubrutinib has been used for 1 year or the disease progresses or the adverse effects, death, withdrawal of informed consent or study termination.

Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1.

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Prospective Single-arm, Single-center Clinical Study of Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Regimen in Relapsed/Refractory Patients With Diffuse Large B-cell Lymphoma

The data of all patients will be stored in the self-owned EDC system of Zhongshan Hospital Affiliated to Fudan University, and the research results will be published in the form of research papers.

the proportion of participants who have achieved complete or partial remission determined by the researcher.

the proportion of subjects evaluated by researchers to obtain CR.

Defined as the proportion of participants with a time of ≥ 2 years from the start of treatment to the first recording of disease progression or death, based on the investigator's assessment of the first occurrence

incidence and severity of adverse events (AE) and Serious adverse event (SAE) during the study

Peng Liu

Professor

Spots Global Cancer Trial Database for zanubrutinib, polatuzumab vedotin and rituximab